Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Increasing survival of ischemic tissue by targeting CD47.

Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, Roberts DD.

Circ Res. 2007 Mar 16;100(5):712-20. Epub 2007 Feb 9.

2.

Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia.

Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2582-8. Epub 2007 Oct 4.

3.

Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation.

Isenberg JS, Shiva S, Gladwin M.

Nitric Oxide. 2009 Aug;21(1):52-62. doi: 10.1016/j.niox.2009.05.005. Epub 2009 May 27.

4.

Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease.

Isenberg JS, Romeo MJ, Maxhimer JB, Smedley J, Frazier WA, Roberts DD.

Ann Surg. 2008 May;247(5):860-8. doi: 10.1097/SLA.0b013e31816c4006.

5.

Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts.

Isenberg JS, Pappan LK, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, Frazier WA, Roberts DD.

Ann Surg. 2008 Jan;247(1):180-90.

6.

Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling.

Isenberg JS, Maxhimer JB, Powers P, Tsokos M, Frazier WA, Roberts DD.

Surgery. 2008 Nov;144(5):752-61. doi: 10.1016/j.surg.2008.07.009. Epub 2008 Sep 2.

7.

Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.

Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD.

J Biol Chem. 2009 Jan 9;284(2):1116-25. doi: 10.1074/jbc.M804860200. Epub 2008 Nov 11.

8.

CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1.

Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD.

J Biol Chem. 2006 Sep 8;281(36):26069-80. Epub 2006 Jul 11.

9.

Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow.

Rogers NM, Roberts DD, Isenberg JS.

Ann Surg. 2013 Jul;258(1):184-91. doi: 10.1097/SLA.0b013e31827e52e1.

10.

Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.

Isenberg JS, Frazier WA, Krishna MC, Wink DA, Roberts DD.

Curr Drug Targets. 2008 Oct;9(10):833-41. Review.

11.

Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective.

Maxhimer JB, Shih HB, Isenberg JS, Miller TW, Roberts DD.

Plast Reconstr Surg. 2009 Dec;124(6):1880-9. doi: 10.1097/PRS.0b013e3181bceec3.

12.

Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation.

Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ, Bauer PM, Schnermann J, Roberts DD, Isenberg JS.

Cardiovasc Res. 2010 Dec 1;88(3):471-81. doi: 10.1093/cvr/cvq218. Epub 2010 Jul 7.

13.

Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury.

Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, Tsokos M, Wink DA, Roberts DD.

Am J Pathol. 2008 Oct;173(4):1100-12. doi: 10.2353/ajpath.2008.080237. Epub 2008 Sep 11.

14.

Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, Wink DA, Isenberg JS, Roberts DD.

Sci Transl Med. 2009 Oct 21;1(3):3ra7. doi: 10.1126/scitranslmed.3000139.

15.

Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.

Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo-Cuaresma M, Pilewski JM, Champion HC, Zuckerbraun BS, Calzada MJ, Isenberg JS.

Cardiovasc Res. 2012 Mar 15;93(4):682-93. doi: 10.1093/cvr/cvr356. Epub 2012 Jan 2.

16.

Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake.

Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD.

J Biol Chem. 2007 May 25;282(21):15404-15. Epub 2007 Apr 5.

17.

Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1.

Csányi G, Yao M, Rodríguez AI, Al Ghouleh I, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, Pagano PJ.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2966-73. doi: 10.1161/ATVBAHA.112.300031. Epub 2012 Oct 18.

18.

Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47.

Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, Frazier WA.

Matrix Biol. 2011 Mar;30(2):154-61. doi: 10.1016/j.matbio.2010.12.004. Epub 2011 Jan 20.

19.

Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD.

J Biol Chem. 2010 Dec 10;285(50):38923-32. doi: 10.1074/jbc.M110.172304. Epub 2010 Oct 5.

20.

Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice.

Soto-Pantoja DR, Shih HB, Maxhimer JB, Cook KL, Ghosh A, Isenberg JS, Roberts DD.

Matrix Biol. 2014 Jul;37:25-34. doi: 10.1016/j.matbio.2014.05.003. Epub 2014 May 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk